A5016655127- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Gut microbiota and health
- Molecular Biology Techniques and Applications
- Clostridium difficile and Clostridium perfringens research
- Immune cells in cancer
- Lymphoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Eosinophilic Disorders and Syndromes
- Ovarian cancer diagnosis and treatment
Sichuan Cancer Hospital
2023
University of Electronic Science and Technology of China
2023
Abstract Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated effects intratumoral on response with ESCC to NACI. Intratumoral signatures β-diversity were disparate predicted efficiency enrichment Streptococcus...
<div>Abstract<p>Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated effects intratumoral on response ESCC to NACI. Intra-tumoral signatures β-diversity were disparate predicted efficiency enrichment...
<p>Table S2 shows clinical characteristics of patients with esophageal squamous cell carcinoma (ESCC) who underwent NACI1 treatment.</p>
<p>Supplementary methods</p>
<p>Supplementary figure legend</p>
<p>Figure S4 shows intra-tumoral bacteria identified in patients with ESCC.</p>
<p>Table S5 shows sequences of the primers used for qRT-PCR.</p>
<p>Table S4 shows reagents and antibodies.</p>
<p>Table S2 shows clinical characteristics of patients with esophageal squamous cell carcinoma (ESCC) who underwent NACI1 treatment.</p>
<p>Table S3 shows clinical characteristics of feces providers for fecal microbiota transplantation.</p>
<p>Table S1 shows clinical characteristics of esophageal squamous cell carcinoma (ESCC) patients who underwent upfront surgery.</p>
<p>Figure S6 shows immune cell clusters and signatures revealed by single-cell RNA sequencing in patients with ESCC.</p>
<p>Table S5 shows sequences of the primers used for qRT-PCR.</p>
<p>Table S4 shows reagents and antibodies.</p>
<p>Figure S7 shows fecal microbial transplantation (FMT) influenced the immune microenvironment of subcutaneous xenograft tumor tissues.</p>
<p>Supplementary figure legend</p>
<p>Figure S6 shows immune cell clusters and signatures revealed by single-cell RNA sequencing in patients with ESCC.</p>
<p>Figure S4 shows intra-tumoral bacteria identified in patients with ESCC.</p>
<p>Figure S5 shows intra-tumoral Microbiota associated with activated immune cell infiltration.</p>
<p>Figure S3 shows bacterial components differed between the NACI responders and non-responders of ESCC patients.</p>
<p>Table S3 shows clinical characteristics of feces providers for fecal microbiota transplantation.</p>
<p>Figure S8 shows intra-tumoral bacterial contents were stable during tumor growth.</p>
<p>Figure S2 shows intra-tumoral microbial diversity of patients with ESCC.</p>
<p>Figure S1 shows detection of intra-tumoral microbiota in the ESCC tissues.</p>
<p>Table S1 shows clinical characteristics of esophageal squamous cell carcinoma (ESCC) patients who underwent upfront surgery.</p>